SCHEMBL2289324

SCHEMBL2289324

COc1cc(O)ccc1C(=O)C=Cc1sc(C)c(CC(C)C)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 3/20 0.54
MAOB P27338 2/20 0.54
PARP1 P09874 1/20 0.54
MAOA P21397 1/20 0.54
CTSL P07711 5/20 0.50
CTSB P07858 3/20 0.47
XDH P47989 1/20 0.46
CHRNA7 P36544 2/20 0.43
TDP1 Q9NUW8 3/20 0.42
ABCG2 Q9UNQ0 3/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NR1H4 Q96RI1 2/20 0.42
ALDH1A1 P00352 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289329 0.79 CTSB (0.54) CAPN1CTSLCTSBCHRNA7TDP1
SCHEMBL1859437 0.71 MAOB (0.50) CAPN1MAOBPARP1MAOACTSL
SCHEMBL2027068 0.71 MAOB (1.00) CAPN1MAOBPARP1MAOACTSL
SCHEMBL799750 0.71 MAOB (1.00) CAPN1MAOBPARP1MAOACTSL
SCHEMBL29634551 0.71 MAOB (1.00) CAPN1MAOBPARP1MAOACTSL
SCHEMBL30383807 0.71 MAOB (1.00) CAPN1MAOBPARP1MAOACTSL
SCHEMBL2457233 0.70 MAOB (0.48) CAPN1MAOBPARP1MAOACTSL
SCHEMBL2292106 0.70 F2 (0.45) MEN1KMT2A
SCHEMBL13359233 0.69 MAOB (0.75) CAPN1MAOBPARP1MAOACTSL
SCHEMBL25217879 0.69 MAOB (0.84) CAPN1MAOBPARP1MAOACTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976512-B1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2015-09-30 EP disclosed
US-8003800-B2 Thiophene derivatives as S1P1/EDG1 receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-23 US disclosed
US-20100240717-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-23 US disclosed
EP-1976512-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2008-10-08 EP disclosed
WO-2007080542-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240717-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS S1PR3, S1PR1, S1PR2 CAPN1 3451/4885MAOB 4461/4885PARP1 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.